Navigation Links
Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5

- Company Outlines Development Plans -

OTTAWA, Canada – March 7, 2007 – Liponex Inc. (TSX:LPX), a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called “good cholesterol,” today announced results of the Phase I/II Clinical Trial of its lead product, CRD5. CRD5 is being developed for the treatment of dyslipidemia and heart disease.

Results showed, to date, that CRD5 was safe and that the drug formulation was stable throughout the trial. However, the mean increase
in HDL levels from the baseline, in both the 1 and 3 gram dosages was less than 5% and not statistically significant. The patient to patient variation was high and while some patients showed a strong increase in HDL, other patients had negative response. The Company will continue to assess the data from this trial over the next several weeks.

“This trial data did not meet expectations consistent with the efficacy data seen in earlier preclinical and clinical studies. However the trial provided us with important information to continue development and we remain confident that this compound is still a viable drug candidate in a hugely attractive market space,” said Bill Dickie, President and CEO of Liponex. “At this point, we can best add value by continuing our formulation development work, culminating in a second Phase I/II trial with results anticipated in early 2008. The goal of this trial will be to finalize a formulation and dose level for a U.S. FDA submission to advance clinical development.”

With cash and short-term investments of approximately $6 million as of December 2006, Liponex believes it has adequate financial resources to complete this trial without the need for additional funding. “Optimizing the oral delivery of lipid-based drugs to consistently give efficacy is complex but, based on our evolving understandin
'"/>




Page: 1 2 3

Related medicine technology :

1. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Liponex Inc Reports Phase Clinical Trial Data for CRD5
(Date:9/1/2015)... 2015 Taiwan,s GNT ... in Taipei on  August 25 ... platform, a targeted drug delivery technology that uses nano-scale ... was part of a joint press conference held by ... (GNT), showcasing GNT,s latest edible gold-based food and beverage ...
(Date:9/1/2015)... 1, 2015 Sargas Pharmaceutical Adherence and ... Drug Adherence m Health applications along with 24 ... of non face-to-face monitoring of twenty minutes per ... of our apps, doctors are now well prepared ... our ONCHIT certified Physician, Pharmacy and Patient portals ...
(Date:9/1/2015)... Agena Bioscience TM today announced the establishment ... commercial and financial hub from which many biotech and life ... in mainland China . "The ... sales with almost sixty MassARRAY ® Systems installed to ... allow us to expand our reach and foster a high ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Agena Bioscience Opens Office in Shanghai, China 2
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
... 23 Each year in the United States more than ... These new cases account for 10 percent of the new ... several types of leukemia, the survival rate has not changed ... Golubieski, president of Foundation Venture Capital Group, LLC, a New ...
Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
(Date:9/1/2015)... ... September 01, 2015 , ... In ... how many dental practices across the country are switching from traditional dental impressions ... Beverly Hills cosmetic dentist Dr. Sam Saleh of Ora Dentistry Spa, his practice ...
(Date:9/1/2015)... , ... September 01, 2015 , ... According to a ... individuals with type 2 diabetes that participated in a three year study about weight ... down the line if they elected weight loss surgery at the onset of the ...
(Date:9/1/2015)... ... , ... Celebrity hairstylist and Beauty Gives Back Art Team member Ted Gibson ... Thursday, Oct. 1, at the La Valencia Hotel. The presentation, on the eve of ... and professional hair, makeup and nail design. , The evening of beauty and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Georgia State ... universities across the country in stemming sexual assaults on their campuses. , The ... a consortium of sexual assault researchers and student affairs professionals responding to calls ...
(Date:9/1/2015)... ... 01, 2015 , ... Splashtop Inc. , the worldwide ... , a solution optimized for MSPs and IT professionals looking for a cost ... inadequate customer services of existing remote support solution, many MSPs and ITs have ...
Breaking Medicine News(10 mins):Health News:Article on CAD/CAM Dental Technology Highlights the Advantages of 21st Century Dentistry, Notes Ora Dentistry Spa 2Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4
... Los Angeles Based ... ... winning video for the “ Ban Asbestos Now! ” film search which is part of a ... health implications due to exposure. Los Angeles residents Arik Cohen (writer/director), Jared Bauer (cameraman), ...
... factors have long been known to play a major role ... obesity suggests that there should be some common changes in ... change in dietary factors in the past few decades is ... However, the effect of long-term exposure to excess niacin on ...
... , This release is available in German ... after an accident or illness, a corneal transplantation could restore ... in Germany, about 7,000 await the opportunity to ... donor corneas are not common. Dr. Joachim Storsberg of the ...
... The 57 million Americans currently living with "pre-diabetes" could ... according to a new study published in this month,s ... a 6-month Weight Watchers group program, overweight or obese adults ... not only lost weight, but also significantly reduced fasting glucose ...
... received a $100,000 Grand Challenges Explorations grant from the ... an innovative global health research project led by Todd ... Mechanical Engineering, titled "Complement-based antibiotic microbeads". Sulchek,s project ... Foundation in the fourth funding round of Grand Challenges ...
... successful testing of a sensor that can instantly tell whether ... by emergency room doctors to determine whether a patient has ... diabetics do not take enough insulin. Someday the technology may ... determine whether they need more insulin. A report on the ...
Cached Medicine News:Health News:Judges Select Winner of the Ban Asbestos Now Video Search 2Health News:Judges Select Winner of the Ban Asbestos Now Video Search 3Health News:Judges Select Winner of the Ban Asbestos Now Video Search 4Health News:Synthetic eye prosthesis 2Health News:New study finds attending Weight Watchers meetings helps reduce the risk for type 2 diabetes 2Health News:Georgia Tech awarded Gates Foundation grant for innovative global health research 2
...
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Medicine Products: